Handling HPV Vaccines And Screening: The Views Of 100 Authors
Amsterdam, 21 September, 2006 - Elsevier is delighted to announce the publication of a unique supplement to the journal Vaccine: HPV Vaccines and Screening in the Prevention of Cervical Cancer. This special monograph provides a comprehensive and invaluable update for paediatricians, gynaecologists, health educators, policy decision makers, industry and major donor institutions worldwide.
With the arrival of the Human Papillomavirus (HPV) vaccines and the progressive introduction of HPV-based screening technology, the field of cervical cancer prevention is expanding into new areas of influence involving an ever-widening group of professionals. Starting with the offer of HPV vaccines to pre-adolescent girls and the optional vaccination of young and middle-age women, HPV vaccines may in some instances be recommended as a universal vaccine for both genders towards the prevention of cervical cancer. “An unprecedented and phenomenal challenge for Public Health in the 21st century”, according to Dr. Xavier Bosch, Guest Editor and driving force behind this monograph; “The background, the results, the challenges and a set of proposals are analyzed by a group of 100 independent experts, leaders in the various relevant fields”.
This monograph was officially launched during the 23rd International Papillomavirus Conference & Clinical Workshop in Prague, Czech Republic at the beginning of September 2006. The full version is available at the Vaccine website. Furthermore, this landmark publication will be available via the HINARI programme, the public-private initiative (launched by the World Health Organization) to bridge the digital divide in health information access .
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect, MD Consult, Scopus, bibliographic databases, and online reference works.
Elsevier is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier’s ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
- Contact Information
- Floris de Hon
- Journal Publisher, Immunology and Virology
- Elsevier, Amsterdam, the Netherlands
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.